



HAL
open science

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

Andrew J. Muir, Fred F. Poordad, John G. Mchutchison, Mitchell L. Shiffman, Thomas Berg, Peter Ferenci, E Jenny Heathcote, Jean-Michel Pawlotsky, Stefan Zeuzem, Henk W. Reesink, et al.

► **To cite this version:**

Andrew J. Muir, Fred F. Poordad, John G. Mchutchison, Mitchell L. Shiffman, Thomas Berg, et al.. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.. *Hepatology*, 2011, 54 (5), pp.1538-46. 10.1002/hep.24549 . inserm-00647300

HAL Id: inserm-00647300

<https://inserm.hal.science/inserm-00647300>

Submitted on 1 Nov 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Table 3. Adverse Events Leading to Discontinuation and Most Common Adverse Events Reported According to Treatment Group

	T12PR24	T12PR48	Unassigned*	Total
n (%)	N = 81	N = 34	N = 2	N = 117
Adverse events leading to discontinuation**	5 (6)	3 (9)	2 (100)	10 (9)
Rash events‡	4 (5)	1 (3)	1 (50)	6 (5)
Pruritus	1 (1)	0 (0)	1 (50)	2 (2)
Pyrexia	1 (1)	1 (3)	0 (0)	2 (2)
Anemia	2 (2)	0 (0)	0 (0)	2 (2)
Adverse events occurring in >10% of patients, n (%)				
Severe adverse event	12 (15)	7 (21)	1 (50)	20 (17)
General disorder				
Fatigue	30 (37)	21 (62)	1 (50)	52 (44)
Influenza-like illness	17 (21)	10 (29)	1 (50)	28 (24)
Pyrexia	16 (20)	6 (18)	0 (0)	22 (19)
Chills	11 (14)	4 (12)	0 (0)	15 (13)
Asthenia	9 (11)	3 (9)	0 (0)	12 (10)
Gastrointestinal disorder				
Nausea	20 (25)	11 (32)	1 (50)	32 (27)
Diarrhea	19 (24)	6 (18)	0 (0)	25 (21)
Hemorrhoids	9 (11)	4 (12)	0 (0)	13 (11)
Skin and subcutaneous disorders				
Pruritus	34 (42)	9 (26)	2 (100)	45 (38)
Rash†	23 (28)	13 (38)	1 (50)	37 (32)
Dry skin	10 (12)	5 (15)	0 (0)	15 (13)
Nervous system disorders				
Headache	23 (28)	14 (41)	0 (0)	37 (32)
Psychiatric disorders				
Insomnia	14 (17)	7 (21)	1 (50)	22 (19)
Depression	9 (11)	4 (12)	0 (0)	13 (11)
Musculoskeletal disorders				
Myalgia	10 (12)	5 (15)	0 (0)	15 (13)
Arthralgia	11 (14)	2 (6)	0 (0)	13 (11)
Respiratory disorders				
Cough	9 (11)	4 (12)	2 (100)	15 (13)
Blood and lymphatic disorders				
Anemia	22 (27)	7 (21)	0 (0)	29 (25)

*Unassigned patients discontinued treatment prior to week 12 assignment of treatment duration.

**Adverse events leading to discontinuation in ≥ 2 patients.

‡This category includes all patients experiencing rash events as assessed with the use of a group of related terms to identify all dermatologic events. All treatment discontinuations due to rash happened during telaprevir phase.

†Using a variety of descriptive terms to identify all dermatologic events, rash events occurred in 44%, 53%, 100%, and 48% of T12PR24, T12PR48, Unassigned, and Total patients, respectively.